AGC’s COVID-19 Response Measures
Amid the global outbreak of coronavirus (COVID-19), the AGC Group is placing top priority on ensuring the health and safety of all stakeholders, including employees and their families, customers, and business partners.
On that basis, the AGC Group is manufacturing products and raw materials that are needed in society while working to ensure the health and safety of employees and their families and prevent the spread of infection.
The following is AGC’s activities to fight against COVID-2019. In over 30 countries and regions, the AGC Group is working to make the world a better place.
News related to COVID-19
- May 14, 2020
- CytoDyn's Drug Candidate for COVID-19 'Leronlimab', Contract Manufactured at AGC, Progressing with Clinical Trials in the US
- May 14, 2020
- AGC to Manufacture COVID-19 Vaccine for AdaptVac
AGC’s products and services against COVID-19
Drug candidate for new coronavirus【In development】
US FDA has approved Phase 2b/3 clinical trials of Leronlimab, a drug candidate for new coronavirus developed by US-based CytoDyn. This drug is contract-manufactured by AGC Biologics, a CDMO subsidiary of AGC.
COVID-19 vaccine【In development】
AGC Biologics (Headquarters: US), a CDMO subsidiary of AGC, is partnering with Denmark-based AdaptVac to manufacture a candidate COVID-19 vaccine.
A hollow structure transparent sheet that is formed by integrally molding a tough polycarbonate sheet with a special technology. It is used as an effective partition for countermeasures against splash infection in offices and cafeterias.
Disinfectant/Deodorizer Spray "ZiaSafe"【On sale】
ZiaSafe is a disinfectant and deodorizer spray made from a dilute solution of sodium hypochlorite.
AGC’s activities against COVID-19
Corporate Communications & Investor Relations Division